Quarterly report pursuant to Section 13 or 15(d)

ACCRUED EXPENSES

v3.22.2.2
ACCRUED EXPENSES
 9 Months Ended
Sep. 30, 2022
Payables and Accruals [Abstract]  
ACCRUED EXPENSES

10. ACCRUED EXPENSES

 

Accrued expenses consisted of the following:

 

 

 

September 30,
2022

 

 

December 31,
2021

 

 

 

 

 

 

 

 

Accrued pre-clinical and clinical costs

 

$

1,405,142

 

 

$

5,435,464

 

Accrued product development costs

 

 

34,262

 

 

 

203,676

 

Accrued compensation

 

 

1,707,393

 

 

 

2,715,368

 

Accrued administrative costs

 

 

721,500

 

 

 

1,213,699

 

Accrued interest

 

 

965,542

 

 

 

525,105

 

Total

 

$

4,833,839

 

 

$

10,093,312